

1 **Comparative activity of silver based antimicrobial composites for urinary catheters**

2
3 **Authors:** Nikhil Thokala^{1, 5}, Dr Carmel Kealey^{2, 4}, Dr James Kennedy³, Dr Damien B.
4 Brady^{2, 4}, Dr Joseph Farrell^{1, 5}. Dept. of Mechanical and Polymer Engineering¹, Dept. of
5 Life & Physical Science², Bioscience Research Institute⁴, Materials Research Institute⁵,
6 Athlone Institute of Technology, Athlone and Kustus³, Grangegorman, Ireland.
7

8 **Corresponding author Dr Damien B Brady**

9 **Contact Details**

10 **Email dbrady@ait.ie**

11 **Tel 00353906468080**

12 **Abstract**

13 **Keywords:** Elemental silver; Ionic silver; Glass carrier; Polymer/antimicrobial composites;
14 Antimicrobial efficacy; Silver ion release.
15

16
17 Biomedical polymers are an integral component in a wide range of medical device designs
18 due to their range of desirable properties. However, extensive use of polymer materials in
19 medical devices have also been associated with an increasing incidence of patient
20 infections. Efforts to address this issue have included the incorporation of antimicrobial
21 additives for developing novel antimicrobial polymeric materials. Silver with its high
22 toxicity towards bacteria, oligodynamic effect and good thermal stability has been
23 employed as an additive for polymeric medical devices. In the present study,
24 commercially available elemental (Biogate) and ionic (Ultrafresh 16) silver additives were
25 incorporated into a Polyamide 11 (PA 11) matrix using a compression press. These
26 polymer composites were evaluated for their antimicrobial and ion release properties.
27 Elemental silver composites were determined to retain their antimicrobial properties for
28 extended periods and actively release silver ions for 84 days; whereas the ionic silver
29 composites lost their ion release activity and therefore antibacterial activity after 56 days.
30 Bacterial log reduction units of 3.87 for ionic silver and 2.41 for elemental silver was
31 identified within 24 hr, when tested in accordance with ISO 22196 test standard;
32 indicating that ionic silver is more efficient for short-term applications compared to
33 elemental silver.
34
35
36

37

38 **1. Introduction**

39 Antimicrobial activity of metallic silver is well established. The use of silver compounds
40 in many different forms including sutures, solutions and colloids to treat a range of
41 infectious diseases was commonplace until the mid-1930s. With the advent of penicillin
42 and other antibiotics, there was a rapid decline in the use of silver and related products for
43 clinical and disinfectant purposes. However, there has been a renewed interest in silver as
44 an antimicrobial agent due to the emergence of the antibiotic resistant strains of bacteria
45 including methicillin-resistant *staphylococcus aureus* (MRSA) and vancomycin-resistant
46 *staphylococcus aureus* (VRSA) and their associated devastating nosocomial infections [1].
47 Public expectation for higher standards in infection prevention and control, has led to a
48 demand for materials capable of killing pathogens on common touch surfaces and on
49 medical device surfaces in hospitals and long-term care facilities. The most significant
50 hospital-acquired infections, based on frequency and potential severity, are those related to
51 the use of devices such as intravascular [2] and urinary catheters [3, 4]. While other
52 compounds with antimicrobial properties are either too volatile or do not withstand
53 thermal processing; noble earth metals like silver and copper, with their excellent thermal
54 and chemical stability, toxic properties towards bacteria at low concentrations have
55 inevitably led to their use as antimicrobial agents in the design of polymeric medical
56 devices [5].

57

58 Elemental silver is relatively inert towards bacteria, ionisation of the elemental silver in
59 the presence of oxygen and moisture results in the release of silver ions, which interacts
60 with the bacterial cell wall surface components to exert their toxicity [6]. In contrast, ionic
61 silver additives comprise a host structure capable of housing silver cations that are
62 released through interaction with moisture [7]. These systems derive their activity on the
63 ability to supply, under the right circumstances, a critical concentration of silver cations
64 necessary for an antimicrobial effect. Silver, in both elemental and ionic form is widely
65 available as an antimicrobial additive. Figure 1 presents commercially available forms of
66 silver antimicrobial additives, including the additives selected for this study.

67

68 Silver ions are effective against nearly all pathogens of concern in healthcare
69 environments, including *Staphylococcus aureus*, *Escherichia coli* and multi drug resistant
70 bacterial strains [8]. Silver ions act by strongly binding to critical biological molecules like

71 proteins, DNA, RNA and disrupting their functions [9]. The mechanisms by which silver
72 particles exert antimicrobial activity begin with the release of silver ions. Binding of silver
73 ions to cell membranes and intracellular absorption is an important first step. Silver ions
74 bind strongly to electron receptors, notably disulphide, amino, carbonyl and phosphate
75 residues on membranes leading to intracellular absorption by phagocytosis [10-14].

76
77 Different methods for the incorporation of silver additive include *in situ* polymerization,
78 direction deposition onto polymer surface and incorporation of the antimicrobial additive
79 into the bulk polymer [15]. To ensure predictability and control of silver ion release, direct
80 incorporation of the antimicrobial into the bulk polymer during the medical device
81 manufacturing stage is likely to be, long term, a far more effective approach. This more
82 direct approach relies on the delivery of minute quantities of ionic metal to the bacterial
83 cell membrane.

84
85 The primary aim of this study was to critically examine elemental and ionic silver
86 additives and understand their behaviour under specific test conditions for 80 days, a much
87 extended period of time than previously conducted. Here we evaluate ionic and elemental
88 silver additives for their ion release and antimicrobial properties. A medical grade
89 Polyamide 11 (PA 11) acted as the host matrix. PA 11 is polar, aliphatic, crystalline
90 homopolymer highly suited for medical applications. An active silver concentration of
91 1600 ppm was selected based on our previous studies with PA 11/copper composites [16].
92 1600 ppm PA 11/silver composites were prepared by compression moulding and
93 examined to develop novel antimicrobial materials for medical device applications such as
94 urinary catheters, which slowly release ionic silver and mitigate bacterial colonization of
95 polymer surfaces. There is an urgent need for antimicrobial catheters that are suitable for
96 long-term use [17, 18]. Antimicrobial catheters that remain infection-free for up to three
97 months could dramatically improve the quality of life of individuals trying to manage
98 intractable urinary problems such as chronic urinary retention.

100 **2. Materials and Powdered Masterbatch Preparation**

101 Silver antimicrobial additives namely Biogate Hymedic 4000 (Biogate, Germany),
102 Ultrafresh 16 (Thomson Reuters, Canada) and Biomaster GC 100 (Addmaster, UK) were
103 selected for this study. The physical properties of these additives, as specified in the

104 technical datasheets as presented in Table 1. Polyamide 11 (Rilsan BMNO) a medical
105 grade semi-crystalline polymer with a melt index value of 11.0 g/10 min was sourced from
106 Arkema, France. Powdered Polyamide 11 was blended with these additives in a household
107 blender at room temperature to make up a 50% w/w powder masterbatches. These
108 uniformly blended powdered masterbatches were further compression moulded providing
109 final active ingredient concentrations of 1600 ppm.

110

111 **2.1 Elemental analysis of antimicrobial additives by Energy/Wave Dispersive X - ray** 112 **spectrum (EDS) coupled with scanning electron microscope (SEM)**

113 Elemental analysis and weight (% w/w) composition of the antimicrobial additives were
114 determined using a Tescan Mira XMU variable pressure scanning electron microscope
115 (SEM) in high vacuum mode coupled with Oxford EDS/WDX (energy/wave dispersive X-
116 ray). The specimen setup was scanned between 10-20 kV at different ranges of
117 magnification. Additional sample treatment such as surface etching or coating with a
118 conductive layer (Gold, ~15nm thick) was applied before surface scanning to provide a
119 path for the incident electrons to flow to ground.

120

121 **2.2 Processing of Antimicrobial Formulations**

122

123 **2.2.1 Compression Moulding**

124 PA 11/Ag test composites of dimensions 35 mm × 35 mm and thickness ca. 0.4 - 0.5 mm,
125 suitable for antimicrobial efficacy and ion release studies were prepared using a Servitex
126 Polystat 200 T compression press at 200 °C. A force of 2 kN was applied for 9 minutes
127 and a final pressure of 38 bar was then applied for one minute.

128

129 **2.3 Antimicrobial studies**

130 *Escherichia coli* strain ATCC 8739, recommended for ISO 22196 test method, was
131 obtained from MicroBioLogics Inc, USA. The test organism, stored at -80 °C on porous
132 beads (Pro-lab diagnostics), was grown overnight in Mueller Hinton and Nutrient broth at
133 37 °C for determining minimum inhibitory concentration of the additives and surface
134 antimicrobial efficacy of PA 11/silver composites respectively. The resulting bacterial
135 suspensions were centrifuged at 10000 rpm for 10 min and the pellet resuspended in

136 sterile phosphate buffered saline (PBS) to give bacterial populations of 1×10^6 CFU/mL
137 for subsequent studies.

138

139

140 **2.3.1 Minimum Inhibitory Concentration (MIC)**

141 The MIC for selected additives were evaluated against *E. coli* ATCC 8739 using the broth
142 dilution method in accordance with Clinical Laboratory Standards Institute (CLSI). 100
143 μ L of the test bacterial population was aseptically transferred into the wells of the
144 microtiter plate and supplied with additive suspensions ranging from 0 μ g/mL to 100
145 μ g/mL. The microtitre plate was then incubated for 16-18 hr at 37 °C at a speed of 125
146 rpm. 100 μ L of the resulting mixtures were then inoculated on to the MH agar plates and
147 incubated for 24 hr at 37 °C. The additive concentrations showing complete reduction in
148 bacterial colonies was recorded as the MIC as presented in Table 2.

149

150 **2.3.2 Disk Diffusion assay**

151 Susceptibility of the test organism, *E. coli* ATCC 8739 to the antimicrobial additive
152 suspensions were determined in accordance with the Kirby Bauer method using a disk
153 diffusion assay. Sterile disks were soaked with antimicrobial suspensions, concentrations
154 ranging 1, 10, 100 and 500 μ g/ml; these disks were then dried at 60 °C for 1 hr and
155 aseptically transferred to the Mueller Hinton agar plates inoculated with test bacterial
156 population. These plates were then incubated for 24 hr at 37 °C and for zones of
157 inhibition determined. Solvent used for suspending the additives, 0.1 N HNO₃ and 30
158 μ g/ml chloramphenicol impregnated antibiotic disks were used as negative and positive
159 controls respectively.

160

161 **2.3.3 Evaluation of antibacterial efficacy of the PA 11/Ag composites**

162 The antimicrobial efficacy of the PA 11/Ag composites were evaluated according to the
163 ISO 22196 standard. In brief, the square test composites (6 untreated and 3 treated with Ag
164 additive) prepared in section 2.2.1 were placed in petri dishes and inoculated with 200 μ L
165 of the test organism. The inoculum was covered with a sterile coverslip (22 mm \times 22 mm),
166 incubated for 24 hr at 37 °C and 95% relative humidity for 3 of the 6 untreated composites
167 and 3 composites treated with silver additive. Test composites were supplied with 10 ml of
168 soyabean casein digest lecithin polysorbate broth (neutralising solution) and ultra-
169 sonicated for 5 min to recover bacteria from surface of the specimens. Remaining 3

170 untreated composites were also processed in this manner prior to the incubation to provide
171 comparative baseline data. Subsequently the recovered bacterial cell suspension was
172 serially diluted in physiological saline. Petri dishes containing plate count agar were
173 inoculated with these recovered bacterial dilutions in duplicates. These plates were
174 incubated for 40-48 hr at 37 °C, after which colony forming units were determined.

175 176 **2.4 Silver ion release kinetics and long-term antimicrobial activity**

177 Ion release studies were carried out using Varian Atomic Absorption Spectrometer.
178 Initially a standard curve was drawn for the 1000 mg/L Ag standard solution obtained
179 from Sigma Aldrich, Ireland. Ion release kinetics were measured for 1600 ppm PA 11/
180 antimicrobial composites by immersing 1 gm of the test composite in 100 ml aqueous
181 mixture (95 ml d. H₂O and 5 ml 0.1 N HNO₃) at 37 °C. The immersion liquid was
182 recovered after 48 hr and thereafter every week, for 8 weeks and quantitatively analysed.
183 Selected PA 11/antimicrobial composites were analysed for long term antimicrobial
184 activity, using the recovered aqueous mixture, similar to the method used for determining
185 the MIC.

186 187 **3. Results and Discussion**

188 189 **3.1 Elemental analysis by EDS (Energy/Wave Dispersive X - ray spectrum)/SEM**

190
191 As shown in Figure 2 elemental silver (Biogate) comprises ~95% (w/w) Ag and ~5%
192 (w/w) carbon. Ionic silver additives, Ultrafresh 16 and Biomaster comprises carbon,
193 oxygen, magnesium, silicon, phosphorous, silver and tungsten. As expected oxygen was
194 found to be the major element followed by phosphorous and carbon. Small quantities of
195 aluminium was identified only in Biomaster. The elements aluminium, magnesium and
196 silicon in the form of their respective oxides acts as the inorganic carrier for the silver
197 ions. Approximately 0.89% (w/w) and 1.28% (w/w) of silver was determined from the
198 elemental analysis of Ultrafresh 16 and Biomaster respectively. Tungsten, which acts as a
199 radio opacifying agent was also observed to be in equal amounts to that of silver in these
200 ionic silver additives.

201 202 **3.2 Determination of MIC**

203 When tested against *E. coli* ATCC 8739 at a working bacterial population of 1×10^6
204 CFU/mL, it was observed that porously designed elemental silver was more effective even
205 at lower concentrations compared to ionic silver. The porous nature and relatively larger
206 surface area of the elemental silver examined might be responsible for its effective
207 bacterial inhibitory activity. The MIC for elemental silver additive was determined to be
208 $1 \mu\text{g/ml}$ whereas, MIC for ionic silver additives Biomaster and Ultrafresh 16 were 10 and
209 $20 \mu\text{g/ml}$ respectively as displayed in Table 2. As there was no real difference in MIC for
210 Ultrafresh and Biomaster, antimicrobial efficacy and ion release studies were continued
211 only with Ultrafresh.

212

213 **3.3 Disk Diffusion**

214 Disk diffusion studies show that *E. coli* ATCC 8739 was susceptible towards ionic
215 antimicrobial additives. Biomaster and Ultrafresh 16 could diffuse through the agar and
216 exhibited clear zones of inhibition. The elemental silver, Biogate did not show zones of
217 inhibition; which may suggest an inferior antibacterial activity on agar plates, as compared
218 to that in liquid medium, as identified from its MIC. It is likely that restricted mobility of
219 the silver ions from the elemental silver additive through the semi-solid agar resulted in its
220 failure to show zones of inhibition. As shown in Figure 3, a maximum of 12.5 mm and 13
221 mm diameter zones of inhibitions were observed at $100 \mu\text{g/ml}$ silver ion concentration for
222 Biomaster and Ultrafresh 16 respectively, which were less compared to the $30 \mu\text{g/ml}$
223 chloramphenicol impregnated disks.

224

225 **3.4 Antimicrobial efficacy of PA 11/silver composites**

226 Surface antimicrobial properties for PA 11/ silver composites were determined in
227 accordance with our previous studies on PA11/copper composites [16]. Test composites
228 with a common active agent loading of 1600 ppm were examined for their antimicrobial
229 efficacies, against a test population of 1×10^6 CFU/mL *E. coli* ATCC 8739 strain.
230 Untreated PA 11 was used as control sample. Figure 4 depicts that untreated PA 11 had no
231 antimicrobial effect, after 24 h exposure the number of viable bacteria increased from
232 1×10^6 CFU/mL to 2.94×10^6 CFU/mL. As per the test standard ISO 22196, to consider an
233 antimicrobial system to be effective in eliminating the test bacteria, it must generate log
234 reduction values in the range of ≥ 2 log units [19]. As presented in Figure 4 the log
235 reduction values were 3.87 and 2.41 for ionic silver (Ultrafresh 16) and elemental silver

236 (Biogate) composites respectively; indicating the bacterial reductions in the range of
237 99.9% to >99.9% within 24 hr.

238

239

240 **3.5 Ion release and long-term antimicrobial efficacy for PA 11/silver composites**

241 The ion release rates for the antimicrobial composites were determined weekly, over an 8-
242 week period. A stable release of silver ion was observed for composites with elemental
243 silver as shown in Figure 5. Few ions were released initially, with a more controlled ion
244 release pattern observed over the course of time suggesting a long-term ion release
245 capability for elemental silver composites. After 7 days, the number of ions released from
246 elemental silver composites could reduce almost 99% of bacterial population. Thereafter
247 >99% reduction in bacterial population was observed for days 14, 21, 28 and 35 with 37,
248 42, 39 and 32 $\mu\text{g/l/g}$ silver ions released into the aqueous mixture. Interestingly a burst
249 release of silver ions was observed for ionic silver composites. 150 $\mu\text{g/l/g}$ silver ions were
250 released within 7 days and the corresponding bacterial reduction values were observed,
251 indicating the number of ions released were directly proportional to the percentage
252 reduction in bacterial population. However, the number of ions released from these ionic
253 systems declined after 7 days and ceased altogether after approximately 56 days. Kumar *et*
254 *al.*, also compared the ion release properties of PA6 composites for a shorter time frame
255 with elementary silver and ionic silver in a carrier and concluded that some of the ionic
256 silver additives showed the burst release effect initially and gradually became inefficient
257 [20]. The polar nature of PA 11 allows diffusion of water molecules into the matrix,
258 resulting in a burst release effect within 2 days for these systems. Although comparable
259 bacterial log reduction values were observed for both the composite systems; elemental
260 silver was more active against *E. coli* ATCC 8739 for extended periods. After 35 days, log
261 reduction values of 2.4 and 1.4 were observed for elemental and ionic silver composites
262 respectively. Furthermore, the elemental silver composites eluted biologically significant
263 numbers of silver ions sufficient to control the bacterial populations. However this work
264 will need to be extended to study other urinary catheter associated pathogens including
265 *Pseudomonas. aeruginosa*, *Klebsiella pneumonia* and *Candida albicans*. In addition the *in*
266 *vitro* activity of the antimicrobial composites would need to be tested in an environment
267 simulating the urinary tract.

268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299

4. Conclusion

In this work antimicrobial susceptibility, antimicrobial efficacy and ion release kinetics of PA 11/silver composites were examined. Ionic silver additive could diffuse through the agar to show zones of inhibition, whereas the elemental silver additive failed to diffuse through agar medium. However, when incorporated into PA 11 and evaluated for polymer surface antimicrobial efficacy in accordance with ISO 22196 standard, both the composite systems were active against *E. coli* ATCC 8739. Bacterial reductions of >99% were observed for these composites within 24 hr. A controlled delivery of silver ions was observed for elemental silver composites with extended ion release profiles. The coinciding long-term antimicrobial efficacy for these composites suggest elemental silver composites ideally suits long-term catheterization. In contrast, ionic silver composites are more suitable for shorter term use to prevent microbial attachment or growth on a catheter surface with a burst release of silver ions within 48 hr.

Acknowledgements

The authors are grateful to Innovative Polymer Compounds (IPC) Ireland for providing PA 11 materials and for permission to use their moulding facilities.

300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328

References

1. Peng JJY, Botelho MG & Matinlinna JP. Silver compounds used in dentistry for caries management: a review. *Journal of Dentistry*, 2012; 40, 521-41.
2. Daneshpour N, Collighan R, Perrie Y, Lambert P, Rathbone D, Lowry D & Griffin M. Indwelling catheters and medical implants with FXIIIa inhibitors: A novel approach to the treatment of catheter and medical device-related infections., *Eur. J. Pharm. Biopharm*, 2013; 83, 106–13.
3. Cooper IR, Pollini M & Paladini F. The potential of photo-deposited silver coatings on Foley catheters to prevent urinary tract infections. *Materials Science & Engineering. C, Materials for Biological Applications*, 2016; 69, 414–20.
4. Fisher LE, Hook AL, Ashraf W, Yousef A, Barrett D, Scurr DJ & Bayston R. Biomaterial modification of urinary catheters with antimicrobials to give long-term broadspectrum antibiofilm activity. *Journal of Controlled Release : Official Journal of the Controlled Release Society*, 2015; 202, 57–64.
5. Palza H. Antimicrobial polymers with metal nanoparticles. *International Journal of Molecular Sciences*, 2015; 16(1), 2099–116.
6. Damm C, Munstedt H & Rosch A. The antimicrobial efficacy of polyamide 6/silver-nano- and microcomposites. *Materials Chemistry and Physics*, 2008;108, 61-66.
7. Anupharb SS, Srihirin T, Thaweboon B, Thaweboon S, Amornsakchai T, Dechkunakorn S & Kamaguchi A. Antimicrobial effects of silver zeolite, silver zirconium phosphate silicate and silver zirconium phosphate against oral microorganisms. *Asian Pacific Journal of Tropical Biomedicine*, 2013; 3(1), 47–52.

- 329 8. Honda M, Kawanobe Y, Ishii K, Konishi T, Mizumoto M, Kanzawa N, Matsumoto M
330 & Aizawa M, In vitro and in vivo antimicrobial properties of silver-containing
331 hydroxyapatite prepared via ultrasonic spray pyrolysis route., *Materials Science &*
332 *Engineering. C, Materials for Biological Applications*, 2013; 33, 5008–18.
- 333 9. Tran PA, Hocking DM & O'Connor AJ. In situ formation of antimicrobial silver
334 nanoparticles and the impregnation of hydrophobic polycaprolactone matrix for
335 medical device applications. *Materials Science & Engineering. C, Materials for*
336 *Biological Applications*, 2015; 47, 63-69.
- 337 10. Monteiro DR, Gorup LF, Takamiya AS, Ruvollo-Filho AC, De Camargo ER, Barbosa
338 DB. The growing importance of materials that prevent microbial adhesion:
339 antimicrobial effect of medical devices containing silver. *International Journal of*
340 *Antimicrobial Agents*, 2009; 34(2), 103–10.
- 341 11. Rai M, Yadav A & Gade A, Silver nanoparticles as a new generation of
342 antimicrobials. *Biotechnology Advances*. 2009; 27, 76–83.
- 343 12. Lansdown AB. A Pharmacological and Toxicological Profile of Silver as an
344 Antimicrobial Agent in Medical Devices. *Advances in Pharmacological Sciences*,
345 2010.
- 346 13. Morones-Ramirez JR, Winkler JA, Spina CS & Collins JJ. Silver enhances antibiotic
347 activity against gram-negative bacteria. *Science Translational Medicine*, 2013;
348 5(190), 190ra81.
- 349 14. McEvoy JG & Zhan Z. Antimicrobial and photocatalytic disinfection mechanisms in
350 silver-modified photocatalysts under dark and light conditions. *Journal of*
351 *Photochemistry and Photobiology C: Photochemistry Reviews*, 2014; 19, 62–75.
- 352 15. Sedlarik V. Antimicrobial modification of polymers:chapter 7, *Intech*, 2013.
- 353 16. Thokala N, Kealey C, Kennedy J, Brady DB & Farrell J. Characterisation of
354 polyamide 11/ copper antimicrobial composites for medical device applications.
355 *Materials Science & Engineering. C, Materials for Biological Applications*, 2017; 78,
356 1179-1186.
- 357 17. Tenke P, Kovacs B, Bjerklund Johansen TE, Matsumoto T, Tambyah PA, Naber KG.
358 European and Asian guidelines on management and prevention of catheter-associated

359 urinary tract infections. *International Journal of Antimicrobial Agents*, 2008; 31 (1),
360 68–78.

361 18. Zhang W, Liu A, Hu D, Xue D, Li C, Zhang K & Ma H. Indwelling versus
362 Intermittent Urinary Catheterization following Total Joint Arthroplasty: A Systematic
363 Review and meta analysis, *PLoS ONE*, 2015; 10(7), 1–13.

364 19. Altan M & Yildirim H. Mechanical and Antibacterial Properties of Injection Molded
365 Polypropylene/TiO₂Nanocomposites : Effects of Surface Modification, *J. Mater. Sci.*
366 *Technol.* 2012; 28(8), 686–692.

367 20. Kumar R & Münstedt H. Polyamide/silver antimicrobials: effect of crystallinity on the
368 silver ion release. *Polymer International*, 2005; 54(8), 1180–1186.

369